Cullinan Therapeutics Inc.
Headquarters country
United States
Registry sponsor category
Industry
- Other names
- Cullinan Therapeutics Inc.
- Company name
- Cullinan Therapeutics Inc.
- Organisation type
- Industry
- Registered legal name
- Cullinan Therapeutics, Inc.
- US industry code (SIC)
- Biological products, (no disgnostic substances)
- Registry sponsor category
- Industry
- SEC filer number (CIK)
- 0001789972
Related records
Trials (12)
- A Phase 1/2 Trial of CLN-081 in Patients With Non-Small Cell Lung Cancer
- A Phase 1b Study of CLN-049 in Combination With Azacitidine and Venetoclax in AML Patients
- A Phase 1b/2a Study of Velinotamig in Adults With Relapsed/Refractory ITP and wAIHA
- A Study of CLN-619 (Anti-MICA/MICB Antibody) in Patients With Relapsed and Refractory Multiple Myeloma
- A Study of CLN-619 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors
- A Study of CLN-978 in Patients With Relapsed or Refractory (R/R) B Cell Non-Hodgkin Lymphoma (B-NHL)
- A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Rheumatoid Arthritis
- A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Sjogren's Disease
- A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Systemic Lupus Erythematosus
- CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
- CLN-617 Alone and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
- Phase 1/2a Study of VK-2019 in Patients With Epstein-Barr Virus (EBV)-Positive Nasopharyngeal Carcinoma (NPC)